New paths for a bispecific road less traveled
Bispecific antibodies targeting two tumor antigens are picking up steam, and their benefits could extend to ADCs
Fresh off their first approval, bispecific antibodies targeting two tumor antigens are picking up steam, and their benefits could extend to ADCs.
As bispecifics against two tumor antigens win their first approval and gain traction at ASCO, drug developers are also eyeing the opportunities this class of compounds could open up for ADCs.
Bispecific antibodies are steadily becoming a must-have for cancer drug developers. The modality has surpassed both mAbs and cell therapies as the focus of pharma oncology deals, and has been a consistent bright spot at cancer meetings, generating clinical data in new target spaces of immuno-oncology that CAR Ts haven’t yet touched.
Although the lion’s share of development in the class has focused on immune cell engagers — compounds that target tumor cells with one arm, and use the other arm to kill them via immune effectors — only